




Please use the headings above to navigate through the different sections of the poster \_\_\_\_\_



different sections of

the poster





navigate through the different sections of the poster



- Rationale
- Objective
- Study Schema
- Methods
- Key Eligibility Criteria
- Intervention
- Enrollment/Status
- Follow Up

Please use the headings above to navigate through the different sections of the poster

## Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Jennifer Ligibel, MD

**Dana-Farber Cancer Institute** 

## Intervention

Weight Loss Intervention

- Telephone-based program, supplemented by print/web-based materials
- Based on Diabetes Prevention Program, Look AHEAD and LISA studies, with updates to nutritional recommendations
- Each participant is paired with a weight loss coach, based at centralized call center at the Dana-Farber Cancer Institute
- Intervention includes 42 planned calls
  over the 2-year intervention
- Target intervention goals include:
  - 10% weight loss (individual); average weight loss goal 7%
  - 500-1000 kcal/day caloric restriction
  - 150-225 minutes of weekly physical activity

## **Health Education Intervention**

- Materials supporting healthy lifestyle (cookbook, water bottle, informational mailings)
- Webinars on focused breast cancer survivorship
- Study newsletter
- Subscription to health magazine














- Protocol open to enrollment at 1984 US and 17 Canadian centers
- Completion of enrollment anticipated 7/2020
- · Primary results anticipated late 2023

	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer		TAP TO RETURN TO
	Jennifer Ligibel, MD Dana-Farber Cancer Institute		KIOSK MENU
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	Funding Support		NCI National Clinical Trials Network
Rationale Objective Study Schema	Alliance A011401 is funded by the National Institutes of Health through National Cancer Institute grant awards, U10CA180821, U10CA180882, U10CA180820, U10CA180868, U10CA077202, and in part by Susan G. Komen Foundation, Breast Cancer Research Foundation, American Cancer Society; in kind: Fitbit Corp, Nestlé Health Science, Osiri Corp. Clinicaltrials.gov identifier: NCT02750826		DANA-FARBER
Methods Key Eligibility Criteria Intervention Enrollment/Status			
Follow Up			
Please use the	Contact Us		
headings above to navigate through the different sections of the poster	E-mail: jligibel@partners.org	Protocol Coordinator: S. Taniya Silva E-mail: stsilva@uchicago.edu Phone: 773-834-4091	
	Primary Statistician: William Barry, PhD E-mail: bbarry@jimmy.harvard.edu Phone: 617-632-5134		